Navigation Links
Hard To Treat Diseases (HTDS) Clinical Trial Update on Therapeutic effects of Combined Treatment With Ribavirin And Tiazofurin
Date:7/1/2009

BELGRADE, SERBIA, July 1 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS) (www.htdsmedical.com) Chief Scientist with its Slavica BioChem subsidiary, Dr. Sanja Pekovic provided updates on recent clinical trials with animal subjects in regards to the use of Ribavirin And Tiazofurin for the potential treatment of Multiple Sclerosis (MS).

Dr. Pekovic reported; "It is now well accepted that axonal injury begins at an early stage in MS, and likely accounts for clinical progression seen later in the disease course, suggesting that early, aggressive treatment is critical in order to suppress long-term disability progression. Researchers from IBISS group (a related research group) tested the effect of combined treatment with ribavirin (R) and tiazofurin (T) administrated during the effecter phase of disease.

Dr. Pekovic added: "We are hopeful, that with additional funding, we will be able to continue along this promising path, and continue researching the potential applications of a combination of ribavirin and tiazofurin in the treatment of MS."

This is a narrative report - release. A full detailed release will be posted on the company's website www.htdsmedical.com shortly.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nation Takes a Big Step Toward Learning Which Medical Treatments Work Best, a Major Advance in Fixing Our Broken Health-Care System
2. The Other Cruciate Ligament: Newer Treatments for PCL Tears
3. New treatment for receding gums: No pain, lots of gain
4. Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration
5. Study identifies biomarker that safely monitors tumor response to new brain cancer treatment
6. Holistic Skin Contouring Treatment Now Offered by Renowned Surgeon - The Results Are Simply Amazing
7. U.S. Doctors Treat Heart Attack With Mans Own Stem Cells
8. Even After Death, Heart Attack Treatment May Not End
9. Measurements fail to identify TB patients who could benefit from shorter treatment course
10. Women with cystic fibrosis can have safe and successful fertility treatment
11. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, ... families throughout the Five Boroughs, is launching a charity drive to raise funds that ... the traditions and spirit of marines and Navy FMF Corpsmen. Working closely with the ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel ... a portion of proceeds to two local organizations: North Chicago Animal Control and Friends ... is a team of authorized and trained volunteers who support rescued animals held ...
(Date:12/7/2016)... ... December 07, 2016 , ... The medical profession is well aware that heart ... major study analyzing heart attacks among 138,602 people recorded a 35% higher number of ... would all agree of course–no time of year is a good time for a ...
(Date:12/7/2016)... Norwalk, CT (PRWEB) , ... December 07, 2016 ... ... the Integrated Infertility and Wellness (IFW) Program at Reproductive Medicine Associates of Connecticut ... which now has a team of three acupuncturists to help patients realize their ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ), ... a company overview at the BMO Capital Markets Prescriptions for Success ... NY . A live webcast of the presentation ... Ionis website.  The replay will be available within 48 hours and ... ...
(Date:12/7/2016)... (NYSE: LCI ) today announced that the company will ... Conference on December 14, 2016 at 9:20 a.m. (ET) at the ... In addition, the company will host one-on-one meetings with ... Boston Healthcare Conference taking place on December 13, 2016 at the ... , , ...
(Date:12/6/2016)... -- Alopexx Oncology, LLC announced data from a Phase I ... composed of interleukin-2 and a CD20-targeting monoclonal antibody. The ... as Rituxan and maintains the activities of both the ... tumor targeting, engagement of the immune system, and induction ... study (abstract #95954) were presented at the 58 th ...
Breaking Medicine Technology: